COMBINATORIAL RAT PANELS FOR PHARMACOGENETIC EFFECTS

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$100,000.00
Award Year:
2002
Program:
SBIR
Phase:
Phase I
Contract:
1R43ES011432-01
Award Id:
60913
Agency Tracking Number:
ES011432
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
PHYSIOGENIX, INC., 10437 INNOVATION DR, STE 329, MILWAUKEE, WI, 53226
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
STEVEN NYE
(414) 771-7469
SNYE@PHYSIOGENIX.COM
Business Contact:
HOWARD JACOB
(414) 305-7469
JACOB@MCW.EDU
Research Institution:
n/a
Abstract
This SBIR Phase I project will create and validate a combinatorial panel of rats designed to detect genetic differences to drug response including toxicity. The genome sequencing projects are bringing new molecular tools to both the pharmacologist and toxicologist. However, each species has its own biological foundations that may lead to misclassification on drug toxicity and result in (1) a high failure rate of new compounds late in clinical trials, (2) unnecessary exposure to human subjects, and (3) the inability to detect small subsets of at-risk individuals in heterogeneous human populations. A need exists for animal model systems that reflect the heterogeneity of the human population while maintaining the phenotypic accuracy of an inbred strain. PhysioGenix, Inc. will determine whether new combinatorial panel of rats fulfills these requirements by measuring both the biochemical and genetic effects of two compounds with well-known toxicity profiles. The molecular basis for the variable drug response will be characterized by gene expression profiling utilizing DNA microarray technology. Phase II efforts will expand the test compounds and tissues used, leading to construction of a database knowledge warehouse. PROPOSED COMMERCIAL APPLICATIONS: About $500 million is spent annually to purchase rats for drug discovery and safety testing. Service-based and Pharmaceutical companies will integrate PhysioGenix' combinatorial rat panel into their pre-clinical drug toxicity studies. Research programs directed at either rescuing previously failed drugs or rationally deriving new compounds will incorporate PhysioGenix tools into their study designs.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government